Federal Register / Vol. 61, No. 123 / Tuesday, June 25, 1996 / Notices 32831

will depend upon the specific meeting

involved. The dates and times reserved

for the separate portions of each

committee meeting are listed above.

The open public hearing portion of

each meeting shall be at least 1 hour

long unless public participation does

not last that long. It is emphasized,

however, that the 1 hour time limit for

an open public hearing represents a

minimum rather than a maximum time

for public participation, and an open

public hearing may last for whatever

longer period the committee

chairperson determines will facilitate

the committee’s work.

Public hearings are subject to FDA’s

guideline (subpart C of 21 CFR part 10)

concerning the policy and procedures

for electronic media coverage of FDA’s

public administrative proceedings,

including hearings before public

advisory committees under 21 CFR part

14. Under 21 CFR 10.205,

representatives of the electronic media

may be permitted, subject to certain

limitations, to videotape, film, or

otherwise record FDA’s public

administrative proceedings, including

presentations by participants.

Meetings of advisory committees shall

be conducted, insofar as is practical, in

accordance with the agenda published

in this Federal Register notice. Changes

in the agenda will be announced at the

beginning of the open portion of a

meeting.

Any interested person who wishes to

be assured of the right to make an oral

presentation at the open public hearing

portion of a meeting shall inform the

contact person listed above, either orally

or in writing, prior to the meeting. Any

person attending the hearing who does

not in advance of the meeting request an

opportunity to speak will be allowed to

make an oral presentation at the

hearing’s conclusion, if time permits, at

the chairperson’s discretion.

The agenda, the questions to be

addressed by the committee, and a

current list of committee members will

be available at the meeting location on

the day of the meeting.

Transcripts of the open portion of the

meeting may be requested in writing

from the Freedom of Information Office

(HFI–35), Food and Drug

Administration, 5600 Fishers Lane, rm.

12A–16, Rockville, MD 20857,

approximately 15 working days after the

meeting, at a cost of 10 cents per page.

The transcript may be viewed at the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1–23,

Rockville, MD 20857, approximately 15

working days after the meeting, between

the hours of 9 a.m. and 4 p.m., Monday

through Friday. Summary minutes of

the open portion of the meeting may be

requested in writing from the Freedom

of Information Office (address above)

beginning approximately 90 days after

the meeting.

The Commissioner has determined for

the reasons stated that those portions of

the advisory committee meetings so

designated in this notice shall be closed.

The Federal Advisory Committee Act

(FACA) (5 U.S.C. app. 2, 10(d)), permits

such closed advisory committee

meetings in certain circumstances.

Those portions of a meeting designated

as closed, however, shall be closed for

the shortest possible time, consistent

with the intent of the cited statutes.

The FACA, as amended, provides that

a portion of a meeting may be closed

where the matter for discussion involves

a trade secret; commercial or financial

information that is privileged or

confidential; information of a personal

nature, disclosure of which would be a

clearly unwarranted invasion of

personal privacy; investigatory files

compiled for law enforcement purposes;

information the premature disclosure of

which would be likely to significantly

frustrate implementation of a proposed

agency action; and information in

certain other instances not generally

relevant to FDA matters.

Examples of portions of FDA advisory

committee meetings that ordinarily may

be closed, where necessary and in

accordance with FACA criteria, include

the review, discussion, and evaluation

of drafts of regulations or guidelines or

similar preexisting internal agency

documents, but only if their premature

disclosure is likely to significantly

frustrate implementation of proposed

agency action; review of trade secrets

and confidential commercial or

financial information submitted to the

agency; consideration of matters

involving investigatory files compiled

for law enforcement purposes; and

review of matters, such as personnel

records or individual patient records,

where disclosure would constitute a

clearly unwarranted invasion of

personal privacy.

Examples of portions of FDA advisory

committee meetings that ordinarily shall

not be closed include the review,

discussion, and evaluation of general

preclinical and clinical test protocols

and procedures for a class of drugs or

devices; consideration of labeling

requirements for a class of marketed

drugs or devices; review of data and

information on specific investigational

or marketed drugs and devices that have

previously been made public;

presentation of any other data or

information that is not exempt from

public disclosure pursuant to the FACA,

as amended; and, deliberation to

formulate advice and recommendations

to the agency on matters that do not

independently justify closing.

This notice is issued under section

10(a)(1) and (a)(2) of the Federal

Advisory Committee Act (5 U.S.C. app.

2), and FDA’s regulations (21 CFR part

14) on advisory committees.

Dated: June 19, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–16174 Filed 6–24–96; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services

Administration

Project Grants for Renovation or

Construction of Non-Acute Health Care

Facilities

AGENCY: Health Resources and Services

Administration.

ACTION: Correction.

SUMMARY: The Notice of Availability of

Funds, Project Grants for Renovation or

Construction of Non-Acute Health Care

Facilities, which was published on June

13, 1996, at 61 FR 30077, is corrected

to include the following areas in Puerto

Rico that were not on the original list:

Appendix I—Metropolitan Areas

Puerto Rico (part):

Loiza Municipio

Luquillo Municipio

Manati Municipio

Mayaguez Municipio

Moca Municipio

Naranjito Municipio

Ponce Municipio

Quebradillas Municipio

Rio Grande Municipio

San German Municipio

San Juan Municipio

San Lorenzo Municipio

Toa Alta Municipio

Toa Baja Municipio

Trujillo Alto Municipio

Vega Alta Municipio

Vega Baja Municipio

Dated: June 20, 1996.

Ciro V. Sumaya,

Administrator.

[FR Doc. 96–16183 Filed 6–24–96; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as
32832 Federal Register / Vol. 61, No. 123 / Tuesday, June 25, 1996 / Notices

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Heart,

Lung, and Blood Special Emphasis

Panel (SEP) meetings:

Name of SEP: Demonstration and

Education Research Grant Applications and

Dietary Patterns, Sodium Intake, and Blood

Pressure (DiPSIBoP).

Date: July 16–17, 1996.

Time: 9:00 a.m.

Place: Washington National Airport Hilton

Arlington, Virginia.

Contact Person: Louise P. Corman, Ph.D.,

Two Rockledge Center, Room 7180, 6701

Rockledge Drive, Bethesda, MD 20892–7924,

(301) 435–0270.

Purpose/Agenda: To review and evaluate

grant applications.

Name of SEP: Angiogenesis and Vascular

Remodeling in the Microvasculature.

Date: July 22–23, 1996.

Time: 7:30 p.m.

Place: Gaithersburg Marriott

Washingtonian Center, 9751 Washington

Boulevard, Gaithersburg, Maryland 20878.

Contact Person: Jon Ranhand, Ph.D., Two

Rockledge Center, Room 7093, 6701

Rockledge Drive, Bethesda, MD 20892–7924,

(301) 435–0280.

Purpose/Agenda: To review and evaluate

grant applications.

These meetings will be closed in

accordance with the provisions set forth in

secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: June 18, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16177 Filed 6–24–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of General Medical

Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Committee Name: National Institute of

General Medical Sciences Special Emphasis

Panel—Program Project Review.

Date: July 18, 1996.

Time: 1:30 p.m.—adjournment.

Place: Club House Inn & Conference

Center, 930 Broadway, Nashville, TN 37203.

Contact Person: Irene B. Glowinski, Ph.D.,

Scientific Review Administrator, NIGMS, 45

Center Drive, Room 1AS–19K, Bethesda, MD

20892–6200.

Purpose: To review and evaluate a program

project application relating to the

determinants of individual responsiveness to

drugs.

This meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The

discussions of these applications could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.821, Biophysics and

Physiological Sciences; 93.859,

Pharmacological Sciences; 93.862, Genetics

Research; 93.863, Cellular and Molecular

Basis of Disease Research; 93.880, Minority

Access Research Careers [MARC]; and

93.375, Minority Biomedical Research

Support [MBRS]).

Dated: June 18, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16178 Filed 6–24–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Mental Health;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Institute of Mental

Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: June 28, 1996.

Time: 10:30 a.m.

Place: River Inn, 924 25th Street NW.,

Washington, DC 20037.

Contact Person: Phyllis D. Artis, Parklawn

Building, Room 9C–26, 5600 Fishers Lane,

Rockville, MD 20857, Telephone: 301, 443–

6470.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less

than fifteen days prior to the meeting

due to the urgent need to meet timing

limitations imposed by the review and

funding cycle.

(Catalog of Federal Domestic Assistance

Program Numbers 93.242, 93.281, 93.282)

Dated: June 18, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16179 Filed 6–24–96; 8:45 am]

BILLING CODE 4140–01–M

National Institutes of Health

National Institute on Deafness and

Other Communication Disorders;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 United States Code

Appendix 2), notice is hereby given of

the following meeting:

Name of Committee: National Institute on

Deafness and Other Communication

Disorders Special Emphasis Panel.

Date: July 15, 1996.

Time: 9:00 a.m. to 12:00 p.m.

Place: Executive Plaza South, Room 400C,

Bethesda, MD (telephone conference call).

Contact Person: Marilyn Semmes, Ph.D.,

Acting Chief, Scientific Review

Administrator, NIDCD/DEA/SRB, EPS Room

400C, 6120 Executive Boulevard, MSC 7180,

Bethesda MD 20892–7180, 301–496–8683.

Purpose Agenda: To review and evaluate

grant applications. The meeting will be

closed in accordance with the provisions set

forth in sections 552b(c)(4) and 552b(c)(6),

Title 5, United States Code. The applications

and/or proposals and the discussion could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which could constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.173 Biological Research

Related of Deafness and Communication

Disorders)

Dated: June 18, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16180 Filed 6–24–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Mental Health;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Institute of Mental

Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: July 18, 1996.

Time: 10 a.m.